29 Nov 2022 , 12:23 PM
Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, as a generic equivalent to Mylan Specialty, L.P.'s Perforomist Inhalation Solution, 20 mcg/2 mL.
In the United States, Formoterol Fumarate Inhalation Solution (RLD Perforomist) had an estimated annual sales of USD 268 million, as per the IQVIA MAT September 2022.
Lupin is a Mumbai-based transnational pharmaceutical company in India that focuses on innovation. The Company develops and commercialises a diverse range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, Asia Pacific (APAC), South Africa, Latin America (LATAM), Europe, and the Middle East.
At around 12.20 PM, Lupin was trading at Rs745.80 up by Rs12.1 or 1.65% from its previous closing of Rs733.70 on the BSE. The scrip touched intraday high and low of Rs759.15 and Rs740.25 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.